July 21, 2026 — Vesalio recently announced that the results from the randomized NATURE clinical trial evaluating the enVast Coronary Thrombectomy System will be presented at the European Society of Cardiology (ESC) Congress 2026, Aug. 28–31 in Munich, Germany.
The NATURE trial (ClinicalTrials.gov Identifier: NCT04969471) is a prospective, multicenter, randomized clinical trial evaluating the safety and effectiveness of the enVast Coronary Thrombectomy System as an adjunctive reperfusion strategy to conventional intervention in STEMI patients with large thrombus burden undergoing primary percutaneous coronary intervention (PCI).
The NATURE study presentation will be in the ESC session focused on optimizing the management of acute myocardial infarction, underscoring the trial's scientific importance and the continued interest in advancing treatment options for patients with ST-segment elevation myocardial infarction (STEMI) and large thrombus burden.
"We are honored that the NATURE trial has been selected as a Late-Breaking Clinical Trial at ESC 2026," said Steve Rybka, Chief Executive Officer of Vesalio. "ESC is the world's largest cardiovascular congress, and this podium presentation is an important milestone for Vesalio and for the investigators who have contributed to this landmark study. We are excited to see the results of the randomized clinical data evaluating enVast presented to the global interventional cardiology community."
Thrombectomy Presentation Details
-
Title: enVast thrombectomy device as adjunctive reperfusion modality in ST-segment elevation myocardial infarction
-
Presenter: Marco Valgimigli, MD, Cardiocentro Ticino Institute, Lugano, Switzerland
-
Session: Late-Breaking Clinical Trials: Optimizing Management of Acute Myocardial Infarction
-
Presentation Date/Time: Aug. 29, 2026
-
Location: ESC Congress 2026, Munich, Germany
June 23, 2026 
